<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>The Ozempic Aftermath: Why Weight Comes Back After GLP-1 Medications — Élan Clinic</title>
  <meta name="description" content="A major Oxford meta-analysis found weight returns four times faster after stopping GLP-1 medications than after stopping diet and exercise alone. Here's what that means — and what actually helps." />
  <link rel="canonical" href="https://elan.clinic/blog/ozempic-aftermath-why-weight-comes-back.html" />
  <link rel="icon" type="image/svg+xml" href="/favicon.svg" />

  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://elan.clinic/blog/ozempic-aftermath-why-weight-comes-back.html" />
  <meta property="og:title" content="The Ozempic Aftermath: Why Weight Comes Back After GLP-1 Medications" />
  <meta property="og:description" content="A major Oxford meta-analysis found weight returns four times faster after stopping GLP-1 medications. Here's what that means — and what actually helps." />
  <meta property="og:locale" content="en_GB" />
  <meta property="article:published_time" content="2026-02-28" />
  <meta property="article:author" content="Dr. Ingmar Lindström" />

  <!-- Schema.org MedicalWebPage Structured Data -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "The Ozempic Aftermath: Why Weight Comes Back After GLP-1 Medications",
    "headline": "The Ozempic Aftermath: Why Weight Comes Back After GLP-1 Medications",
    "url": "https://elan.clinic/blog/ozempic-aftermath-why-weight-comes-back.html",
    "datePublished": "2026-02-28",
    "inLanguage": "en",
    "description": "A major Oxford meta-analysis found weight returns four times faster after stopping GLP-1 medications than after stopping diet and exercise alone. Here's what that means — and what actually helps.",
    "about": {
      "@type": "MedicalCondition",
      "name": "Obesity"
    },
    "medicalAudience": {
      "@type": "MedicalAudience",
      "audienceType": "Patient"
    },
    "author": {
      "@type": "Person",
      "name": "Dr. Ingmar Lindström",
      "jobTitle": "Physician",
      "worksFor": {
        "@type": "MedicalClinic",
        "name": "Élan Clinic",
        "url": "https://elan.clinic"
      }
    },
    "publisher": {
      "@type": "MedicalClinic",
      "name": "Élan Clinic",
      "url": "https://elan.clinic",
      "logo": "https://elan.clinic/favicon.svg",
      "telephone": "+37252999399",
      "address": {
        "@type": "PostalAddress",
        "streetAddress": "Sepapaja 12/1",
        "addressLocality": "Tallinn",
        "postalCode": "11415",
        "addressCountry": "EE"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://elan.clinic/blog/ozempic-aftermath-why-weight-comes-back.html"
    },
    "citation": [
      {
        "@type": "ScholarlyArticle",
        "name": "Weight regain after discontinuation of GLP-1 receptor agonists: a systematic review and meta-analysis",
        "author": "Avgerinos I et al.",
        "isPartOf": { "@type": "Periodical", "name": "BMJ" },
        "datePublished": "2026"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 trial extension",
        "author": "Wilding JPH et al.",
        "isPartOf": { "@type": "Periodical", "name": "Diabetes, Obesity and Metabolism" },
        "datePublished": "2022"
      }
    ]
  }
  </script>

  <!-- Google Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet" />

  <style>
    /* ─── Reset & Base ─────────────────────────────────────────────── */
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }

    html { scroll-behavior: smooth; font-size: 16px; }

    body {
      font-family: 'Inter', sans-serif;
      background-color: #0D1B2A;
      color: rgba(232, 228, 222, 0.55);
      line-height: 1.7;
      -webkit-font-smoothing: antialiased;
    }

    h1, h2, h3, h4 {
      font-family: 'Playfair Display', serif;
      color: #E8E4DE;
      line-height: 1.2;
      font-weight: 500;
    }

    a { color: #C5A55A; text-decoration: none; }
    a:hover { text-decoration: underline; }

    /* ─── Layout ───────────────────────────────────────────────────── */
    .container {
      width: 100%;
      max-width: 1200px;
      margin: 0 auto;
      padding: 0 24px;
    }

    /* ─── Gold Utilities ───────────────────────────────────────────── */
    .label {
      display: inline-block;
      font-family: 'Inter', sans-serif;
      font-size: 0.7rem;
      font-weight: 600;
      letter-spacing: 0.18em;
      text-transform: uppercase;
      color: #C5A55A;
      margin-bottom: 20px;
    }

    .gold-line {
      width: 48px;
      height: 2px;
      background: #C5A55A;
      margin: 28px 0;
    }

    /* ─── Nav ──────────────────────────────────────────────────────── */
    .nav {
      position: fixed;
      top: 0;
      left: 0;
      right: 0;
      z-index: 100;
      padding: 20px 24px;
      display: flex;
      align-items: center;
      justify-content: space-between;
      background: rgba(13, 27, 42, 0.92);
      backdrop-filter: blur(12px);
      border-bottom: 1px solid rgba(197, 165, 90, 0.12);
    }

    .nav__logo {
      font-family: 'Playfair Display', serif;
      font-size: 1.25rem;
      color: #E8E4DE;
      letter-spacing: 0.06em;
      text-decoration: none;
    }

    .nav__logo span { color: #C5A55A; }

    .nav__links {
      display: flex;
      align-items: center;
      gap: 32px;
      list-style: none;
    }

    .nav__links a {
      font-size: 0.78rem;
      font-weight: 500;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      color: rgba(232, 228, 222, 0.65);
      text-decoration: none;
      transition: color 0.2s;
    }

    .nav__links a:hover,
    .nav__links a.active { color: #C5A55A; }

    /* ─── Breadcrumb ───────────────────────────────────────────────── */
    .breadcrumb {
      padding: 120px 0 0;
      background-color: #0D1B2A;
    }

    .breadcrumb__inner {
      display: flex;
      align-items: center;
      gap: 8px;
      flex-wrap: wrap;
    }

    .breadcrumb__item {
      font-size: 0.75rem;
      font-weight: 500;
      letter-spacing: 0.08em;
      color: rgba(232, 228, 222, 0.4);
      text-transform: uppercase;
    }

    .breadcrumb__item a {
      color: rgba(232, 228, 222, 0.4);
      text-decoration: none;
      transition: color 0.2s;
    }

    .breadcrumb__item a:hover {
      color: #C5A55A;
      text-decoration: none;
    }

    .breadcrumb__sep {
      font-size: 0.7rem;
      color: rgba(197, 165, 90, 0.4);
    }

    .breadcrumb__item--current {
      color: #C5A55A;
    }

    /* ─── Article Header ───────────────────────────────────────────── */
    .article-header {
      padding: 48px 0 64px;
      background-color: #0D1B2A;
      position: relative;
      overflow: hidden;
    }

    .article-header::before {
      content: '';
      position: absolute;
      top: -100px;
      right: -150px;
      width: 500px;
      height: 500px;
      background: radial-gradient(circle, rgba(197,165,90,0.05) 0%, transparent 70%);
      pointer-events: none;
    }

    .article-header__content {
      max-width: 780px;
    }

    .article-header h1 {
      font-size: clamp(2rem, 4.5vw, 3.2rem);
      line-height: 1.15;
      margin-bottom: 28px;
    }

    .article-meta {
      display: flex;
      align-items: center;
      flex-wrap: wrap;
      gap: 24px;
      padding-top: 24px;
      border-top: 1px solid rgba(197, 165, 90, 0.15);
    }

    .article-meta__item {
      display: flex;
      align-items: center;
      gap: 8px;
      font-size: 0.8rem;
      color: rgba(232, 228, 222, 0.5);
    }

    .article-meta__item strong {
      color: rgba(232, 228, 222, 0.75);
      font-weight: 500;
    }

    .article-meta__dot {
      width: 3px;
      height: 3px;
      border-radius: 50%;
      background: rgba(197, 165, 90, 0.4);
    }

    /* ─── Article Body ─────────────────────────────────────────────── */
    .article-body {
      padding: 0 0 100px;
      background-color: #0D1B2A;
    }

    .article-body__inner {
      max-width: 780px;
    }

    .article-body p {
      font-size: 1.05rem;
      color: rgba(232, 228, 222, 0.72);
      line-height: 1.85;
      margin-bottom: 28px;
    }

    .article-body h2 {
      font-size: clamp(1.5rem, 2.5vw, 2rem);
      margin: 56px 0 20px;
      color: #E8E4DE;
    }

    .article-body h3 {
      font-size: clamp(1.1rem, 2vw, 1.35rem);
      margin: 40px 0 16px;
      color: #E8E4DE;
    }

    .article-body strong {
      color: rgba(232, 228, 222, 0.9);
      font-weight: 600;
    }

    .article-body em {
      color: rgba(232, 228, 222, 0.65);
      font-style: italic;
    }

    .article-body hr {
      border: none;
      height: 1px;
      background: rgba(197, 165, 90, 0.15);
      margin: 48px 0;
    }

    /* ─── Pull Quote ───────────────────────────────────────────────── */
    .pull-quote {
      border-left: 3px solid #C5A55A;
      padding: 20px 32px;
      margin: 40px 0;
      background: rgba(197, 165, 90, 0.04);
    }

    .pull-quote p {
      font-family: 'Playfair Display', serif;
      font-size: 1.2rem !important;
      font-style: italic;
      color: rgba(232, 228, 222, 0.82) !important;
      line-height: 1.6 !important;
      margin: 0 !important;
    }

    /* ─── Key Stat ─────────────────────────────────────────────────── */
    .key-stat {
      background: #111D2E;
      border: 1px solid rgba(197, 165, 90, 0.18);
      padding: 32px 36px;
      margin: 40px 0;
    }

    .key-stat__number {
      font-family: 'Playfair Display', serif;
      font-size: 3rem;
      color: #C5A55A;
      line-height: 1;
      margin-bottom: 8px;
    }

    .key-stat__label {
      font-size: 0.88rem;
      color: rgba(232, 228, 222, 0.6);
      line-height: 1.5;
    }

    /* ─── Article Sources ──────────────────────────────────────────── */
    .article-sources {
      margin-top: 60px;
      padding-top: 32px;
      border-top: 1px solid rgba(197, 165, 90, 0.12);
    }

    .article-sources p {
      font-size: 0.82rem !important;
      color: rgba(232, 228, 222, 0.38) !important;
      line-height: 1.6 !important;
      margin-bottom: 8px !important;
    }

    .article-sources .sources-label {
      font-size: 0.7rem;
      font-weight: 600;
      letter-spacing: 0.15em;
      text-transform: uppercase;
      color: #C5A55A;
      margin-bottom: 16px;
      display: block;
    }

    /* ─── Back Link ────────────────────────────────────────────────── */
    .back-link {
      display: inline-flex;
      align-items: center;
      gap: 8px;
      font-size: 0.78rem;
      font-weight: 600;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      color: rgba(232, 228, 222, 0.5);
      text-decoration: none;
      transition: color 0.2s, gap 0.2s;
      margin-bottom: 60px;
    }

    .back-link:hover {
      color: #C5A55A;
      gap: 12px;
      text-decoration: none;
    }

    /* ─── Footer CTA ───────────────────────────────────────────────── */
    .footer-cta {
      background-color: #111D2E;
      border-top: 1px solid rgba(197, 165, 90, 0.12);
      text-align: center;
      padding: 100px 24px;
    }

    .footer-cta h2 {
      max-width: 620px;
      margin: 0 auto 24px;
      font-size: clamp(1.6rem, 3vw, 2.2rem);
    }

    .footer-cta__sub {
      max-width: 480px;
      margin: 0 auto 40px;
      font-size: 0.95rem;
    }

    /* ─── Button ───────────────────────────────────────────────────── */
    .btn {
      display: inline-block;
      padding: 16px 36px;
      font-family: 'Inter', sans-serif;
      font-size: 0.85rem;
      font-weight: 600;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      border: 1.5px solid #C5A55A;
      color: #C5A55A;
      background: transparent;
      cursor: pointer;
      transition: background 0.2s, color 0.2s;
      text-decoration: none;
    }

    .btn:hover {
      background: #C5A55A;
      color: #0D1B2A;
      text-decoration: none;
    }

    .btn--filled {
      background: #C5A55A;
      color: #0D1B2A;
    }

    .btn--filled:hover {
      background: #d4b56a;
      color: #0D1B2A;
    }

    /* ─── Footer Legal ─────────────────────────────────────────────── */
    .footer-legal {
      background-color: #0D1B2A;
      border-top: 1px solid rgba(197, 165, 90, 0.08);
      padding: 40px 24px;
    }

    .footer-legal__inner {
      max-width: 1200px;
      margin: 0 auto;
      display: flex;
      flex-direction: column;
      gap: 8px;
    }

    .footer-legal p {
      font-size: 0.75rem;
      color: rgba(232, 228, 222, 0.3);
      line-height: 1.6;
    }

    /* ─── Responsive ───────────────────────────────────────────────── */
    @media (max-width: 768px) {
      .nav__links {
        gap: 16px;
      }

      .nav__links a {
        font-size: 0.72rem;
      }

      .breadcrumb {
        padding-top: 100px;
      }

      .article-header {
        padding: 32px 0 48px;
      }

      .article-body p {
        font-size: 0.98rem;
      }

      .key-stat__number {
        font-size: 2.4rem;
      }

      .pull-quote {
        padding: 16px 20px;
      }
    }
  </style>
</head>
<body>

  <!-- ─── Navigation ────────────────────────────────────────────── -->
  <nav class="nav">
    <a href="/" class="nav__logo">Élan<span>.</span></a>
    <ul class="nav__links">
      <li><a href="/">Home</a></li>
      <li><a href="/blog.html" class="active">Articles</a></li>
      <li><a href="/faq.html">FAQ</a></li>
      <li style="margin-left:8px;border-left:1px solid rgba(197,165,90,0.25);padding-left:16px;"><a href="/et.html" style="font-size:0.7rem;">EST</a></li>
    </ul>
  </nav>

  <!-- ─── Breadcrumb ────────────────────────────────────────────── -->
  <div class="breadcrumb">
    <div class="container">
      <nav class="breadcrumb__inner" aria-label="Breadcrumb">
        <span class="breadcrumb__item"><a href="/">Home</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item"><a href="/blog.html">Articles</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item breadcrumb__item--current">The Ozempic Aftermath</span>
      </nav>
    </div>
  </div>

  <!-- ─── Article Header ───────────────────────────────────────── -->
  <header class="article-header">
    <div class="container">
      <div class="article-header__content">
        <span class="label">GLP-1 Medications · Weight Management</span>
        <h1>The Ozempic Aftermath: Why Weight Comes Back After GLP-1 Medications</h1>
        <div class="article-meta">
          <div class="article-meta__item">
            <strong>Dr. Ingmar Lindström</strong>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            <time datetime="2026-02-28">February 28, 2026</time>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            7 min read
          </div>
        </div>
      </div>
    </div>
  </header>

  <!-- ─── Article Body ──────────────────────────────────────────── -->
  <main class="article-body">
    <div class="container">
      <div class="article-body__inner">

        <p>
          A person sits across from me — let's call her Maris. She lost 18 kilograms on semaglutide over the course of a year. She felt better than she had in a decade. Her blood pressure normalised. Her cholesterol improved. Then, for reasons that had nothing to do with the drug failing her — cost, side effects, pregnancy planning, a doctor who said "let's take a break" — she stopped.
        </p>

        <p>
          Six months later, she was back in my office. Half the weight had returned.
        </p>

        <p>
          She wasn't doing anything wrong. She wasn't cheating or lazy or lacking willpower. She was experiencing exactly what a major new meta-analysis, published in the <em>BMJ</em> and conducted by researchers at the University of Oxford, has now confirmed with the kind of scientific clarity that leaves little room for debate.
        </p>

        <hr />

        <h2>What the Oxford study actually found</h2>

        <p>
          The research team analysed 37 studies involving 9,341 participants — people who had used GLP-1 receptor agonists (medications like semaglutide, liraglutide, and tirzepatide) and then stopped. What they found was sobering, though not entirely surprising to anyone who works in obesity medicine.
        </p>

        <p>
          After stopping GLP-1 medications, people regain weight at a rate of approximately <strong>0.4 kilograms per month</strong>. At that pace, most people return to their pre-treatment weight within roughly <strong>1.7 years</strong> of stopping.
        </p>

        <div class="pull-quote">
          <p>The rate of regain after GLP-1 discontinuation is four times faster than the rate of regain after stopping diet and exercise interventions alone.</p>
        </div>

        <p>
          Read that again, because it matters.
        </p>

        <p>
          When someone stops a structured diet or exercise programme, weight comes back — that's well-documented. But when someone stops a GLP-1 medication, it comes back significantly faster. The Oxford researchers also found that the cardiometabolic benefits — the improvements in blood pressure, cholesterol, and blood sugar that make these drugs genuinely life-changing — also reverse, on average within about <strong>1.4 years</strong> of stopping.
        </p>

        <div class="key-stat">
          <div class="key-stat__number">67%</div>
          <div class="key-stat__label">of people in the STEP-1 extension trial regained two-thirds of their lost weight within just 12 months of stopping semaglutide.</div>
        </div>

        <p>
          One more number worth sitting with: <strong>50% of people stop GLP-1 medications within the first year</strong> of starting them. That means the majority of people using these drugs will go through discontinuation — and very few of them have a structured plan for what comes next.
        </p>

        <hr />

        <h2>Why does this happen? It's biology, not failure</h2>

        <p>
          This is the part of the conversation that matters most, and it's the part that tends to get lost in the headlines.
        </p>

        <p>
          GLP-1 receptor agonists work, in part, by mimicking a hormone your body naturally produces — glucagon-like peptide-1 — which regulates appetite, slows gastric emptying, and improves insulin signalling. When you're on the medication, your brain receives signals that reduce hunger and increase satiety. Your appetite is genuinely, physiologically quieter.
        </p>

        <p>
          When you stop the medication, those signals stop too.
        </p>

        <p>
          Your body doesn't "remember" the weight you lost. It doesn't recalibrate to your new set point. Obesity is a chronic, relapsing condition driven by complex hormonal and neurological feedback loops — and those loops don't get permanently rewired by a course of medication, in the same way that blood pressure doesn't stay low once you stop an antihypertensive.
        </p>

        <p>
          There's also an adaptive component. During weight loss, the body downregulates its metabolic rate, increases hunger hormones like ghrelin, and decreases satiety hormones like leptin. These adaptations are the body's way of defending its previous weight — what researchers call "set point" — and they can persist for years after weight is lost.
        </p>

        <div class="pull-quote">
          <p>None of this is a character flaw. It's physiology.</p>
        </div>

        <hr />

        <h2>"Just stay on it forever" — why that's not always the answer</h2>

        <p>
          The obvious response to all of this is: fine, then people should simply stay on the medication indefinitely. And for some people, that is the right answer. Long-term use of GLP-1 drugs, in appropriate candidates, is medically reasonable and increasingly well-supported by evidence.
        </p>

        <p>
          But "stay on it forever" isn't a complete solution for several reasons that deserve honest acknowledgment.
        </p>

        <p>
          <strong>Access and cost.</strong> In many countries, these medications are not covered by insurance for weight management. Monthly costs can run to several hundred euros. For a large proportion of people, long-term use simply isn't financially viable — and that's a systemic problem, not a personal one.
        </p>

        <p>
          <strong>Side effects.</strong> A meaningful percentage of people experience nausea, vomiting, gastrointestinal discomfort, or other adverse effects that make long-term continuation difficult or impossible. Some people genuinely cannot tolerate the drugs at doses that are effective for them.
        </p>

        <p>
          <strong>Medical contraindications.</strong> Pregnancy, certain thyroid conditions, pancreatitis history — there are real, legitimate reasons why some people stop, and will need to stop again in the future.
        </p>

        <p>
          <strong>Personal choice.</strong> People have agency over their own treatment. Some will decide, in consultation with their doctor, to take breaks, taper doses, or stop entirely. A good medical approach prepares for that reality rather than pretending it won't happen.
        </p>

        <p>
          The Oxford study is important not because it tells us GLP-1 medications don't work — they clearly do — but because it forces a harder, more honest conversation about what happens when they stop, and whether we're preparing people for that moment.
        </p>

        <hr />

        <h2>What actually helps during and after</h2>

        <p>
          This is where the conversation needs to go, and where — frankly — the current medical system often falls short.
        </p>

        <p>
          GLP-1 medications create a window. A genuinely valuable window in which appetite is reduced, metabolic markers improve, and change feels possible. What happens inside that window — and what gets built for life after it — determines a lot of the long-term outcome.
        </p>

        <p>Here's what the evidence supports:</p>

        <p>
          <strong>Structured behavioural support during treatment.</strong> The trials that show the best long-term outcomes aren't just "take the drug." They include dietary counselling, physical activity guidance, and behavioural coaching. The medication lowers the volume on appetite; the behavioural work teaches new habits that can persist independently.
        </p>

        <p>
          <strong>Resistance training as a priority.</strong> Weight loss from GLP-1 drugs includes a significant proportion of muscle mass alongside fat — a concern that's receiving more attention as longer-term data accumulates. Preserving and building muscle through resistance training matters for metabolic rate, functional capacity, and long-term weight maintenance. This is not optional; it's a core component of any serious weight management approach.
        </p>

        <p>
          <strong>Tapering and transition planning.</strong> For people who will stop medication, a thoughtful tapering plan — and a clear nutritional and behavioural strategy for the post-medication phase — can meaningfully reduce the velocity of regain. This is not standard practice in most clinical settings today. It should be.
        </p>

        <p>
          <strong>Psychological support.</strong> The emotional dimension of weight loss and regain is significant and under-addressed. Body image, relationship with food, the grief of regain, the shame spiral that often accompanies it — these are real and they influence outcomes. Integrating psychological support into weight management isn't a luxury.
        </p>

        <p>
          <strong>Ongoing monitoring.</strong> Regular check-ins — even outside of active medication use — help catch early regain and prompt timely response. Weight regain rarely happens all at once; it happens gradually, and catching it early makes intervention easier.
        </p>

        <p>
          The honest truth is that none of this is easy, and none of it comes standard. Most people stopping GLP-1 medications do so without a structured handoff plan, without post-discontinuation behavioural support, and without clear guidance on what to watch for. The Oxford data shows us — clearly — what the cost of that gap is.
        </p>

        <hr />

        <h2>Looking forward</h2>

        <p>
          This study is a useful corrective to a certain kind of optimism that has crept into conversations about GLP-1 medications — the idea that these drugs are a definitive solution, full stop. They're not. They're a remarkable tool, arguably the most effective pharmacological tool we've had in obesity medicine, but a tool embedded in a much larger picture.
        </p>

        <p>
          What integrative weight management looks like, at its best, is medication used thoughtfully as part of a system — one that includes nutrition, movement, behavioural support, psychological care, and a plan that accounts for the full arc of treatment, including what comes after.
        </p>

        <p>
          The people who maintain their results over the long term tend to be the people who used the medication window to build something: habits that don't require the drug to sustain them, a relationship with food and movement that is genuinely different from where they started, and a support structure that doesn't disappear when the prescription ends.
        </p>

        <p>
          That's a harder thing to build than a prescription to write. But it's the thing that matters.
        </p>

        <p>
          The Oxford study isn't a reason to be afraid of GLP-1 medications. It's a reason to be more thoughtful about how we use them — and more honest about what people need before, during, and after.
        </p>

        <!-- ─── Sources ─────────────────────────────────────────── -->
        <div class="article-sources">
          <span class="sources-label">Sources</span>
          <p>Avgerinos I et al. "Weight regain after discontinuation of GLP-1 receptor agonists: a systematic review and meta-analysis." <em>BMJ</em>, 2026.</p>
          <p>Wilding JPH et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 trial extension." <em>Diabetes, Obesity and Metabolism</em>, 2022.</p>
        </div>

        <!-- ─── Back Link ──────────────────────────────────────── -->
        <a href="/blog.html" class="back-link">← Back to Articles</a>

      </div>
    </div>
  </main>

  <!-- ─── Footer CTA ────────────────────────────────────────────── -->
  <section class="footer-cta">
    <span class="label">Consultation</span>
    <h2>Start With a Conversation.</h2>
    <p class="footer-cta__sub">
      A 45-minute consultation where we assess your situation and build a plan for long-term weight maintenance — tailored to your life and your body.
    </p>
    <a href="tel:+37252999399" class="btn btn--filled">Call +372 52 99939</a>
  </section>

  <!-- ─── Footer Legal ──────────────────────────────────────────── -->
  <footer class="footer-legal">
    <div class="footer-legal__inner">
      <p>© 2026 Élan Clinic · Elan Clinic OÜ · Reg 17338832 · Medical licence L07470 · Sepapaja 12/1, Tallinn 11415</p>
      <p>This article is for informational purposes only and does not constitute medical advice. Consult your physician before changing any medication or health programme.</p>
    </div>
  </footer>

</body>
</html>
